Details for Patent: 10,590,418

« Back to Dashboard

Summary for Patent: 10,590,418

Title:	Methods and compositions for RNAi mediated inhibition of gene expression in mammals
Abstract:	Methods and compositions are provided for modulating, e.g., reducing, viral coding sequence expression in mammals and mammalian cells. In the subject methods, an effective amount of an RNAi agent, e.g., an interfering ribonucleic acid (such as an siRNA or shRNA) or a transcription template thereof, e.g., a DNA encoding an shRNA, is introduced into a target cell, e.g., by being administered to a mammal that includes the target cell, e.g., via a hydrodynamic administration protocol. Also provided are RNAi agent pharmaceutical preparations for use in the subject methods. The subject methods and compositions find use in a variety of different applications, including academic and therapeutic applications.
Inventor(s):	Mark A. Kay, Anton McCaffrey
Assignee:	Leland Stanford Junior University
Application Number:	US10/259,226
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 10,590,418

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 10,590,418

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	556720
Australia	2003270912
Australia	2009200231
Canada	2454183